Oncology Companion Diagnostics Market Size, Share, Growth and Forecast (2026 - 2036)
Oncology Companion Diagnostics Market is segmented by Product (Immunohistochemistry Assays, Polymerase Chain Reaction Based Tests, In Situ Hybridization Assays, Next Generation Sequencing Based Tests, Liquid Biopsy Tests, Gene Expression Profiling Tests, Point of Care Companion Diagnostics), Biomarker Type (Genetic Biomarkers, Protein Biomarkers, Cell Surface Biomarkers, Circulating Biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Hematological Cancers), and Region, with forecasts covering the period from 2026 to 2036.
Oncology Companion Diagnostics Market Analysis and Forecast by Fact.MR
- The global oncology companion diagnostics market is estimated at US$ 5.40 billion in 2025 and is forecast to expand at a CAGR of 9.3% to reach US$ 14.36 billion by 2036.
- The oncology companion diagnostics category spans immunohistochemistry assays, biomarker antibody panels, protein expression assays, and related therapeutic approaches addressing genetic biomarkers and mutation based biomarkers.
- Growth reflects rising disease prevalence, expanding clinical evidence, and increasing healthcare access across both developed and emerging markets.
- Regulatory approvals, payer coverage expansion, and physician familiarity with newer therapeutic mechanisms are contributing to sustained demand across the forecast period.
Summary of Oncology Companion Diagnostics Market
- Market Snapshot
- In 2025, the global Oncology Companion Diagnostics Market was valued at approximately USD 5.40 billion.
- The market is estimated to reach USD 5.90 billion in 2026 and is projected to attain USD 14.36 billion by 2036.
- The oncology companion diagnostics market is likely to expand at a CAGR of 9.3% during the forecast period.
- The market is anticipated to create an absolute dollar opportunity of USD 8.46 billion between 2026 and 2036.
- Immunohistochemistry Assays is expected to lead the product segment in 2026.
- China (11.6%) and USA (10.4%) are the key growth markets during the forecast period.
- Demand and Growth Drivers
- Rising disease prevalence and improving diagnosis rates are expanding the addressable patient population across both developed and emerging healthcare systems.
- Growing clinical evidence and real-world data supporting treatment efficacy are strengthening physician confidence and prescribing patterns in specialty care settings.
- Expanding regulatory approvals and payer coverage decisions are improving patient access and reducing out-of-pocket treatment barriers in major markets.
- Increasing investment in specialty pharmacy infrastructure and patient support programs is supporting treatment initiation and long-term adherence.
- Product and Segment View
- Immunohistochemistry Assays is expected to lead the product segment in 2026, supported by established clinical adoption and broad availability.
- Genetic Biomarkers is anticipated to account for the largest share of the biomarker type segment, reflecting concentrated treatment demand.
- Breast Cancer is projected to lead the cancer type segment, supported by clinical preference and treatment protocol alignment.
- Key segmentation includes:
- Product: Immunohistochemistry Assays, Biomarker Antibody Panels, Protein Expression Assays, Polymerase Chain Reaction Based Tests, Real Time Polymerase Chain Reaction Kits
- Biomarker Type: Genetic Biomarkers, Mutation Based Biomarkers, Fusion Gene Biomarkers, Protein Biomarkers, Receptor Expression Biomarkers
- Cancer Type: Breast Cancer, HER2 Positive Breast Cancer, Hormone Receptor Positive Breast Cancer, Lung Cancer, Non Small Cell Lung Cancer
- Technology: Polymerase Chain Reaction Technology, Quantitative Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Next Generation Sequencing Technology, High Throughput Sequencing
- End User: Hospitals, Tertiary Care Hospitals, Cancer Specialty Hospitals, Diagnostic Laboratories, Centralized Diagnostic Labs
- These systems enable:
- Targeted therapeutic intervention in specific disease pathways
- Patient-specific treatment optimization and adherence support
- Clinical outcome monitoring and long-term disease management
- Geography and Competitive Outlook
- North America is a major market, supported by established healthcare infrastructure, strong payer coverage, and high treatment adoption rates.
- Europe is expected to maintain steady growth, supported by structured market access frameworks and specialty treatment networks.
- Asia Pacific is emerging as a growth region, with expanding healthcare investment and rising clinical awareness supporting demand.
- China (11.6%) and USA (10.4%) are the fastest-growing country markets during the forecast period.
- Key companies include F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN, Thermo Fisher Scientific Inc..
- Analyst Opinion
- Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The oncology companion diagnostics market is entering a phase where growth depends on geographic expansion, payer negotiations, and real-world evidence generation. Markets with structured reimbursement pathways are absorbing demand faster. Companies combining strong clinical evidence with effective distribution are capturing disproportionate share. The next growth layer depends on how manufacturers address access barriers in mid-income markets while defending pricing in established geographies.'
Key Growth Drivers, Constraints, and Opportunities
Key Factors Driving Growth
- Rising demand for early and accurate disease detection is driving adoption of immunohistochemistry assays, biomarker antibody panels, protein expression assays across hospital laboratories, reference labs, and point-of-care settings in both developed and emerging markets.
- Increasing prevalence of genetic biomarkers and mutation based biomarkers and the shift toward precision medicine are expanding test volumes and broadening the clinical utility of advanced diagnostic platforms.
- Regulatory streamlining of companion diagnostic approvals and growing integration of immunohistochemistry assays, biomarker antibody panels, protein expression assays into clinical decision-making pathways are supporting sustained demand and reimbursement coverage across major geographies.
Key Market Constraints
- High capital investment requirements for advanced diagnostic platforms and limited reimbursement coverage for newer assays create adoption barriers, particularly in resource-constrained healthcare settings.
- Lack of standardised testing protocols and varying regulatory requirements across geographies create complexity in the commercial rollout of immunohistochemistry assays, biomarker antibody panels, protein expression assays across multiple markets.
- Workforce shortages in laboratory medicine and limited access to trained pathologists in emerging markets constrain test volumes and delay the adoption of advanced genetic biomarkers and mutation based biomarkers technologies.
Key Opportunity Areas
- Expansion of companion diagnostic requirements in oncology and immunology is creating new test-linked treatment pathways, driving demand for validated immunohistochemistry assays, biomarker antibody panels, protein expression assays across clinical settings.
- Integration of artificial intelligence and digital pathology with genetic biomarkers and mutation based biomarkers platforms is enhancing diagnostic accuracy and throughput, supporting premium positioning and adoption growth.
- Growing point-of-care testing adoption and decentralised laboratory networks in emerging markets are creating incremental demand for portable and rapid-turnaround immunohistochemistry assays, biomarker antibody panels, protein expression assays solutions.
Segment-wise Analysis of the Oncology Companion Diagnostics Market
- Immunohistochemistry Assays is expected to lead the product segment in 2026, supported by established adoption, broad clinical utility, and availability across major markets.
- Genetic Biomarkers is anticipated to account for the largest share of the biomarker type segment, reflecting concentrated treatment demand and clinical prioritization.
- Hospitals is projected to lead the end user segment, supported by established treatment infrastructure and prescribing patterns.
The oncology companion diagnostics market is segmented by product, biomarker type, cancer type, technology, end user, and region. By product, the market covers immunohistochemistry assays, biomarker antibody panels, protein expression assays, polymerase chain reaction based tests. By biomarker type, coverage includes genetic biomarkers, mutation based biomarkers, fusion gene biomarkers, protein biomarkers. Immunohistochemistry Assays leads by value in the near term due to established demand, while emerging segments are expected to gain share over the forecast period.
Which Product Segment Leads the Oncology Companion Diagnostics Market?
Immunohistochemistry Assays is estimated to account for the largest share of the product segment in 2026. Demand is concentrated in established treatment settings where clinical evidence, physician familiarity, and payer coverage support continued adoption. The segment benefits from broad availability across specialty and general healthcare channels.
The biomarker antibody panels sub-segment is also gaining traction as clinical protocols evolve and treatment guidelines incorporate newer approaches, reflecting expanding indications and improving evidence bases.
Which Biomarker Type Segment Leads the Oncology Companion Diagnostics Market?
Genetic Biomarkers is expected to lead the biomarker type segment in 2026, reflecting the largest patient population and deepest clinical evidence base. Demand is supported by established diagnosis pathways, treatment protocols, and payer coverage across major geographies.
Mutation Based Biomarkers represent a growing portion of demand, supported by expanding clinical research and regulatory attention, diversifying the revenue base over the forecast period.
Which Technology Segment Leads the Oncology Companion Diagnostics Market?
Polymerase Chain Reaction Technology is anticipated to lead the technology segment in 2026, supported by clinical preference and established infrastructure across major healthcare settings.
Alternative technology options are gaining share as treatment settings diversify and home-based care options expand, supporting broader access.
Which Product Trend is Shaping the Next Phase of Growth in the Oncology Companion Diagnostics Market?
Biomarker Antibody Panels are not yet the largest segment, but they are emerging as a growth area within the oncology companion diagnostics market. Their share is projected to rise as clinical evidence strengthens, regulatory approvals expand, and treatment protocols increasingly incorporate newer mechanisms. This is relevant for patient populations where existing options have not fully addressed treatment goals.
The shift toward newer approaches reflects changing clinical and commercial expectations. Providers and payers are evaluating treatment value based on long-term outcomes, patient convenience, and total cost of care. Products offering differentiated mechanisms or improved adherence profiles are moving from niche positions into more central roles within the treatment pathway.
Regional Outlook Across Key Markets
.webp "Top Country Growth Comparison Oncology Companion Diagnostics Market Cagr (2026 2036)")
- China leads growth at 11.6%, supported by expanding healthcare access and rising treatment adoption.
- North America shows stable growth, with established healthcare infrastructure and strong payer coverage supporting continued demand.
- Europe maintains steady adoption, with structured market access frameworks and specialty treatment networks supporting growth.
- Asia Pacific is emerging as a growth region, with healthcare investment and rising clinical awareness creating incremental demand.
CAGR Table
| Country | CAGR (%) |
|---|---|
| China | 11.6% |
| USA | 10.4% |
| Japan | 10.1% |
| Germany | 9.9% |
| UK | 9.4% |
| Brazil | 8.7% |
| Saudi Arabia | 8.2% |
Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.
Market Outlook for Oncology Companion Diagnostics in China
Centralized drug procurement through volume-based purchasing and NRDL listing decisions are expanding access to immunohistochemistry assays, biomarker antibody panels, protein expression assays in China. Urban tertiary hospital expansion and domestic biologics capacity growth support rising diagnosis and treatment rates.
- NRDL inclusion and provincial reimbursement programs expand patient access in tier-1 and tier-2 cities.
- Domestic clinical trial activity and technology self-sufficiency programs support local capacity development.
USA Oncology Companion Diagnostics Demand Trends
Demand for immunohistochemistry assays, biomarker antibody panels, protein expression assays in the USA is concentrated in specialty care centers and academic medical systems. Inflation Reduction Act provisions and evolving payer coverage models are reshaping pricing dynamics across the treatment landscape.
- Hospital system consolidation is centralizing procurement decisions for specialty products.
- Insurance coverage expansion for approved therapies supports patient access and volume growth.
Oncology Companion Diagnostics Growth Assessment in Japan
PMDA approval pathways and NHI pricing revisions shape demand for immunohistochemistry assays, biomarker antibody panels, protein expression assays in Japan. An aging population profile and established preference for domestic suppliers influence both therapy adoption rates and supply chain positioning.
- NHI price revisions and biennial repricing cycles affect commercial sustainability.
- Aging demographics increase prevalence of conditions requiring specialty care and sustained treatment.
Germany Oncology Companion Diagnostics Market Growth Outlook
Demand for immunohistochemistry assays, biomarker antibody panels, protein expression assays in Germany is shaped by structured health technology assessment processes and national reference pricing. The GKV system and hospital consolidation trends influence both formulary placement and procurement volumes.
- EU MDR compliance creates regulatory alignment for parallel access across neighboring markets.
- Reference pricing and budget impact assessments shape commercial positioning and payer negotiations.
Oncology Companion Diagnostics Demand Analysis in UK
NICE health technology assessments and NHS procurement frameworks shape demand for immunohistochemistry assays, biomarker antibody panels, protein expression assays in the UK. Post-Brexit regulatory divergence and specialty commissioning pathways influence both market access timelines and formulary placement.
- NICE appraisal outcomes determine NHS commissioning decisions and patient access schemes.
- Specialty referral networks and regional treatment centers concentrate prescribing volume.
Brazil Oncology Companion Diagnostics Opportunity Outlook
Demand for immunohistochemistry assays, biomarker antibody panels, protein expression assays in Brazil is supported by federal procurement programs and growing private healthcare sector investment. ANVISA approval timelines and price control frameworks shape commercial entry and positioning.
- Local manufacturing incentives and technology transfer programs support domestic supply development.
- Patient advocacy organizations and rare disease protocols are improving therapy inclusion in public formularies.
Oncology Companion Diagnostics Expansion Trajectory in Saudi Arabia
Vision 2030 healthcare investment and expanding specialty care capacity support demand for immunohistochemistry assays, biomarker antibody panels, protein expression assays in Saudi Arabia. IKTVA local content requirements and alignment with international treatment protocols are shaping procurement decisions.
- Vision 2030 programs are building specialty treatment infrastructure across major hospital groups.
- International benchmark alignment in clinical protocols supports adoption of globally approved therapies.
Competitive Benchmarking and Company Positioning
Oncology Companion Diagnostics Market Analysis By Company
- F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN hold established positions in the global oncology companion diagnostics market through broad product portfolios, regulatory approvals, and commercial infrastructure.
- Thermo Fisher Scientific Inc., Foundation Medicine, Inc., Myriad Genetics, Inc., BIOMÉRIEUX participate across specific market segments, geographic regions, and distribution channels with competition shaped by clinical evidence and pricing strategy.
- Competition centers on clinical differentiation, market access capability, and commercial execution, with F. Hoffmann-La Roche Ltd accounting for approximately 14% of global market share.
F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN hold established positions in the global oncology companion diagnostics market through broad product portfolios, regulatory approvals across major markets, and established commercial infrastructure supporting sustained market presence.
Thermo Fisher Scientific Inc., Foundation Medicine, Inc., Myriad Genetics, Inc., BIOMÉRIEUX, Abbott, Leica Biosystems Nussloch GmbH, Guardant Health participate across specific therapeutic segments, geographic markets, and distribution channels, with competition shaped by clinical evidence depth, pricing strategy, and payer access positioning.
The competitive landscape is moderately fragmented, with F. Hoffmann-La Roche Ltd accounting for approximately 14% of global market share. Competition centers on clinical differentiation, geographic market access, and commercial execution.
Key Companies in the Oncology Companion Diagnostics Market
- F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN are among the leading players in the oncology companion diagnostics market, supported by established product portfolios, strong commercial presence, and regulatory approvals across major markets.
- Thermo Fisher Scientific Inc., Foundation Medicine, Inc., Myriad Genetics, Inc., BIOMÉRIEUX hold positions across specific therapeutic areas, geographic markets, and distribution networks, contributing to a competitive market structure.
- Abbott, Leica Biosystems Nussloch GmbH, Guardant Health maintain relevance through focused product offerings, regional presence, and specialized capabilities within the broader market.
Recent Industry Developments
- F. Hoffmann-La Roche Ltd - Geographic Expansion / Market Access (2026)
- F. Hoffmann-La Roche Ltd expanded commercial availability of its oncology companion diagnostics portfolio into additional markets, strengthening geographic coverage and patient access across underserved regions. The expansion supports broader treatment uptake and aligns with the company's long-term growth strategy in the genetic biomarkers category.
- Agilent Technologies, Inc. - Clinical Program Advancement / Pipeline Update (2025)
- Agilent Technologies, Inc. reported progress in its clinical development program targeting mutation based biomarkers, supporting potential portfolio expansion in the oncology companion diagnostics market. The advancement reflects continued investment in clinical evidence generation and therapeutic differentiation.
- Illumina, Inc. - Distribution Partnership / Channel Expansion (2025)
- Illumina, Inc. entered into a distribution partnership to strengthen market access and availability of its oncology companion diagnostics products across key growth markets. The partnership supports penetration in regions where specialty distribution infrastructure is still developing.
Leading Companies Shaping the Oncology Companion Diagnostics Market
- F. Hoffmann-La Roche Ltd
- Agilent Technologies, Inc.
- Illumina, Inc.
- QIAGEN
- Thermo Fisher Scientific Inc.
- Foundation Medicine, Inc.
- Myriad Genetics, Inc.
- BIOMÉRIEUX
- Abbott
- Leica Biosystems Nussloch GmbH
- Guardant Health
Sources and Research References
- F. Hoffmann-La Roche Ltd. Product portfolio and market activity updates.
- Agilent Technologies, Inc.. Clinical development and commercial expansion updates.
- Illumina, Inc.. Distribution and market access updates.
- Industry association statistics, regulatory agency publications, clinical trial registries, and company product catalogs.
- Primary interviews with manufacturers, distributors, clinicians, payers, and institutional end users.
This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.
Key Questions This Report Addresses
What is the current and future size of the Oncology Companion Diagnostics Market?
- How fast is the oncology companion diagnostics market expected to grow between 2026 and 2036?
- Which product segment is likely to lead the market by 2026?
- Which biomarker type segment is expected to account for the highest demand by 2026?
- What factors are supporting demand globally?
- How is the shift toward newer treatment approaches influencing the market?
- Why is China emerging as a fast-growing market?
- How are regulatory and reimbursement conditions supporting demand in key geographies?
- Which countries are projected to show the fastest growth through 2036?
- What is supporting market expansion in China, USA, and Japan?
- Who are the key companies active in the Oncology Companion Diagnostics Market?
- How does Fact.MR estimate and validate the market forecast?
Oncology Companion Diagnostics Market Definition
The oncology companion diagnostics market covers immunohistochemistry assays, biomarker antibody panels, protein expression assays used across genetic biomarkers, mutation based biomarkers, fusion gene biomarkers applications. The scope includes global and regional forecasts for 2026 to 2036 across product, biomarker type, cancer type, technology, end user, and region.
Oncology Companion Diagnostics Market Inclusions
- The scope covers global and regional market size and forecasts for 2026 to 2036 across product, biomarker type, cancer type, technology, end user, and region.
- It includes regional demand analysis across major geographies, based on factors such as disease prevalence, treatment access, regulatory conditions, and clinical adoption patterns.
- The report includes competitive landscape analysis covering product portfolios, pricing strategy, geographic reach, and distribution positioning of leading players.
- It covers technology trends, market drivers and constraints, and the regulatory environment shaping demand across major markets.
Oncology Companion Diagnostics Market Exclusions
- The scope excludes general healthcare products and services not specifically related to oncology companion diagnostics applications.
- It excludes investigational therapies and compounds in pre-clinical or early-stage development without commercial availability during the forecast period.
- The report excludes compounded or unlicensed preparations without commercial market visibility.
- It also excludes diagnostic devices, screening tools, and support services sold independently of therapeutic products.
Oncology Companion Diagnostics Market Research Methodology
- The methodology combines secondary research, primary interviews, and forecast modelling.
- It draws on 120+ secondary sources and benchmarks 65+ company product portfolios.
- Market sizing covers 30+ countries through a demand-side model with top-down validation.
- Key inputs include disease prevalence, treatment rates, pricing benchmarks, and regulatory timelines.
- Primary validation includes 25+ interviews across manufacturers, distributors, clinicians, and payers.
- Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.
Scope of Analysis
| Parameter | Details |
|---|---|
| Quantitative Units | USD 5.90 billion to USD 14.36 billion, at a CAGR of 9.3% |
| Market Definition | The Oncology Companion Diagnostics Market covers immunohistochemistry assays, biomarker antibody panels, protein expression assays used across genetic biomarkers, mutation based biomarkers, fusion gene biomarkers applications. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | China, USA, Japan, Germany, UK, Brazil, Saudi Arabia, and 30 plus countries |
| Key Companies | F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., Illumina, Inc., QIAGEN, Thermo Fisher Scientific Inc., Foundation Medicine, Inc., Myriad Genetics, Inc., BIOMÉRIEUX, Abbott, Leica Biosystems Nussloch GmbH, Guardant Health |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid demand-side and top-down methodology built on country-level demand analysis, product benchmarking, pricing analysis, primary interviews across manufacturers, distributors, clinicians, and end users |
Oncology Companion Diagnostics Market Segmentation
-
Oncology Companion Diagnostics Market Segmented by Product:
- Immunohistochemistry Assays
- Biomarker Antibody Panels
- Protein Expression Assays
- Polymerase Chain Reaction Based Tests
- Real Time Polymerase Chain Reaction Kits
- Digital Polymerase Chain Reaction Systems
- In Situ Hybridization Assays
- Fluorescence In Situ Hybridization Probes
- Chromogenic In Situ Hybridization Kits
- Next Generation Sequencing Based Tests
- Targeted Gene Panels
- Whole Exome Sequencing Panels
- Liquid Biopsy Tests
- Circulating Tumor DNA Assays
- Circulating Tumor Cell Assays
- Gene Expression Profiling Tests
- Multigene Expression Panels
- Tumor Signature Panels
- Point of Care Companion Diagnostics
- Rapid Molecular Diagnostic Kits
- Bedside Oncology Testing Devices
- Immunohistochemistry Assays
-
Oncology Companion Diagnostics Market Segmented by Biomarker Type:
- Genetic Biomarkers
- Mutation Based Biomarkers
- Fusion Gene Biomarkers
- Protein Biomarkers
- Receptor Expression Biomarkers
- Enzyme Activity Biomarkers
- Cell Surface Biomarkers
- Membrane Protein Markers
- Immune Checkpoint Biomarkers
- Circulating Biomarkers
- Cell Free DNA Biomarkers
- Circulating Tumor Cells Biomarkers
- Genetic Biomarkers
-
Oncology Companion Diagnostics Market Segmented by Cancer Type:
- Breast Cancer
- HER2 Positive Breast Cancer
- Hormone Receptor Positive Breast Cancer
- Lung Cancer
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
- Colorectal Cancer
- KRAS Mutated Colorectal Cancer
- MSI High Colorectal Cancer
- Prostate Cancer
- Androgen Receptor Positive Prostate Cancer
- Metastatic Prostate Cancer
- Melanoma
- BRAF Mutated Melanoma
- High Risk Melanoma
- Hematological Cancers
- Leukemia Based Diagnostics
- Lymphoma Based Diagnostics
- Breast Cancer
-
Oncology Companion Diagnostics Market Segmented by Technology:
- Polymerase Chain Reaction Technology
- Quantitative Polymerase Chain Reaction
- Multiplex Polymerase Chain Reaction
- Next Generation Sequencing Technology
- High Throughput Sequencing
- Clinical Sequencing Platforms
- Immunoassay Technology
- Enzyme Linked Immunosorbent Assay
- Chemiluminescent Immunoassays
- Hybridization Technology
- Fluorescence Hybridization Platforms
- Chromogenic Detection Systems
- Digital Pathology Technology
- AI Assisted Pathology Imaging
- Whole Slide Imaging Systems
- Polymerase Chain Reaction Technology
-
Oncology Companion Diagnostics Market Segmented by End User:
- Hospitals
- Tertiary Care Hospitals
- Cancer Specialty Hospitals
- Diagnostic Laboratories
- Centralized Diagnostic Labs
- Reference Testing Laboratories
- Research Institutes
- Oncology Research Centers
- Academic Medical Centers
- Pharmaceutical and Biotechnology Companies
- Drug Development Organizations
- Clinical Trial Sponsors
- Hospitals
-
Oncology Companion Diagnostics Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- North America
- Frequently Asked Questions -
How big is the oncology companion diagnostics market in 2026?
The global oncology companion diagnostics market is estimated to be valued at USD 5.9 billion in 2026.
What will be the size of oncology companion diagnostics market in 2036?
The market size for the oncology companion diagnostics market is projected to reach USD 14.4 billion by 2036.
How much will be the oncology companion diagnostics market growth between 2026 and 2036?
The oncology companion diagnostics market is expected to grow at a 9.3% CAGR between 2026 and 2036.
What are the key product types in the oncology companion diagnostics market?
The key product types in oncology companion diagnostics market are immunohistochemistry assays, polymerase chain reaction based tests, in situ hybridization assays, next generation sequencing based tests, liquid biopsy tests, gene expression profiling tests, point of care companion diagnostics
Which biomarker type segment is expected to contribute significant share in the oncology companion diagnostics market in 2026?
In terms of biomarker type, genetic biomarkers segment is expected to command 34.2% share in the oncology companion diagnostics market in 2026.
Table of Content
- Executive Summary
- Global Market Outlook
- Demand to side Trends
- Supply to side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Company Annual and Sustainability Reports
- Peer-reviewed Journals and Academic Literature
- Corporate Websites, Product Literature, and Technical Notes
- Earnings Decks and Investor Briefings
- Statutory Filings and Regulatory Disclosures
- Technical White Papers and Standards Notes
- Trade Journals, Industry Magazines, and Analyst Briefs
- Conference Proceedings, Webinars, and Seminar Materials
- Government Statistics Portals and Public Data Releases
- Press Releases and Reputable Media Coverage
- Specialist Newsletters and Curated Briefings
- Sector Databases and Reference Repositories
- Fact.MR Internal Proprietary Databases and Historical Market Datasets
- Subscription Datasets and Paid Sources
- Social Channels, Communities, and Digital Listening Inputs
- Additional Desk Sources
- Expert Input and Fieldwork (Primary Evidence)
- Primary Modes
- Qualitative Interviews and Expert Elicitation
- Quantitative Surveys and Structured Data Capture
- Blended Approach
- Why Primary Evidence is Used
- Field Techniques
- Interviews
- Surveys
- Focus Groups
- Observational and In-context Research
- Social and Community Interactions
- Stakeholder Universe Engaged
- C-suite Leaders
- Board Members
- Presidents and Vice Presidents
- R&D and Innovation Heads
- Technical Specialists
- Domain Subject-matter Experts
- Scientists
- Physicians and Other Healthcare Professionals
- Governance, Ethics, and Data Stewardship
- Research Ethics
- Data Integrity and Handling
- Primary Modes
- Tooling, Models, and Reference Databases
- Desk Research Programme (Secondary Evidence)
- Data Engineering and Model Build
- Data Acquisition and Ingestion
- Cleaning, Normalisation, and Verification
- Synthesis, Triangulation, and Analysis
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y to o to Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Product
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Product, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Product, 2026 to 2036
- Immunohistochemistry Assays
- Biomarker Antibody Panels
- Protein Expression Assays
- Polymerase Chain Reaction Based Tests
- Real Time Polymerase Chain Reaction Kits
- Digital Polymerase Chain Reaction Systems
- In Situ Hybridization Assays
- Fluorescence In Situ Hybridization Probes
- Chromogenic In Situ Hybridization Kits
- Next Generation Sequencing Based Tests
- Targeted Gene Panels
- Whole Exome Sequencing Panels
- Liquid Biopsy Tests
- Circulating Tumor DNA Assays
- Circulating Tumor Cell Assays
- Gene Expression Profiling Tests
- Multigene Expression Panels
- Tumor Signature Panels
- Point of Care Companion Diagnostics
- Rapid Molecular Diagnostic Kits
- Bedside Oncology Testing Devices
- Immunohistochemistry Assays
- Y to o to Y Growth Trend Analysis By Product, 2021 to 2025
- Absolute $ Opportunity Analysis By Product, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Biomarker Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Biomarker Type, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Biomarker Type, 2026 to 2036
- Genetic Biomarkers
- Mutation Based Biomarkers
- Fusion Gene Biomarkers
- Protein Biomarkers
- Receptor Expression Biomarkers
- Enzyme Activity Biomarkers
- Cell Surface Biomarkers
- Membrane Protein Markers
- Immune Checkpoint Biomarkers
- Circulating Biomarkers
- Cell Free DNA Biomarkers
- Circulating Tumor Cells Biomarkers
- Genetic Biomarkers
- Y to o to Y Growth Trend Analysis By Biomarker Type, 2021 to 2025
- Absolute $ Opportunity Analysis By Biomarker Type, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Cancer Type
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Cancer Type, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Cancer Type, 2026 to 2036
- Breast Cancer
- HER2 Positive Breast Cancer
- Hormone Receptor Positive Breast Cancer
- Lung Cancer
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
- Colorectal Cancer
- KRAS Mutated Colorectal Cancer
- MSI High Colorectal Cancer
- Prostate Cancer
- Androgen Receptor Positive Prostate Cancer
- Metastatic Prostate Cancer
- Melanoma
- BRAF Mutated Melanoma
- High Risk Melanoma
- Hematological Cancers
- Leukemia Based Diagnostics
- Lymphoma Based Diagnostics
- Breast Cancer
- Y to o to Y Growth Trend Analysis By Cancer Type, 2021 to 2025
- Absolute $ Opportunity Analysis By Cancer Type, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Technology
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Technology, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Technology, 2026 to 2036
- Polymerase Chain Reaction Technology
- Quantitative Polymerase Chain Reaction
- Multiplex Polymerase Chain Reaction
- Next Generation Sequencing Technology
- High Throughput Sequencing
- Clinical Sequencing Platforms
- Immunoassay Technology
- Enzyme Linked Immunosorbent Assay
- Chemiluminescent Immunoassays
- Hybridization Technology
- Fluorescence Hybridization Platforms
- Chromogenic Detection Systems
- Digital Pathology Technology
- AI Assisted Pathology Imaging
- Whole Slide Imaging Systems
- Polymerase Chain Reaction Technology
- Y to o to Y Growth Trend Analysis By Technology, 2021 to 2025
- Absolute $ Opportunity Analysis By Technology, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End User
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End User, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End User, 2026 to 2036
- Hospitals
- Tertiary Care Hospitals
- Cancer Specialty Hospitals
- Diagnostic Laboratories
- Centralized Diagnostic Labs
- Reference Testing Laboratories
- Research Institutes
- Oncology Research Centers
- Academic Medical Centers
- Pharmaceutical and Biotechnology Companies
- Drug Development Organizations
- Clinical Trial Sponsors
- Hospitals
- Y to o to Y Growth Trend Analysis By End User, 2021 to 2025
- Absolute $ Opportunity Analysis By End User, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Key Takeaways
- Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Key Takeaways
- Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Key Takeaways
- Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Key Takeaways
- East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Key Takeaways
- South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Key Takeaways
- Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- By Country
- Market Attractiveness Analysis
- By Country
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Product
- By Biomarker Type
- By Cancer Type
- By Technology
- By End User
- Competition Analysis
- Competition Deep Dive
- F. Hoffmann-La Roche Ltd
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Agilent Technologies, Inc.
- Illumina, Inc.
- QIAGEN
- Thermo Fisher Scientific Inc.
- Foundation Medicine, Inc.
- Myriad Genetics, Inc.
- BIOMÉRIEUX
- Abbott
- Leica Biosystems Nussloch GmbH
- Guardant Health
- F. Hoffmann-La Roche Ltd
- Competition Deep Dive
- Assumptions & Acronyms Used
List Of Table
- Table 1: Global Market Value (USD Million) Forecast by Region, 2021 to 2036
- Table 2: Global Market Value (USD Million) Forecast by Product, 2021 to 2036
- Table 3: Global Market Value (USD Million) Forecast by Biomarker Type, 2021 to 2036
- Table 4: Global Market Value (USD Million) Forecast by Cancer Type, 2021 to 2036
- Table 5: Global Market Value (USD Million) Forecast by Technology, 2021 to 2036
- Table 6: Global Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 7: North America Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 8: North America Market Value (USD Million) Forecast by Product, 2021 to 2036
- Table 9: North America Market Value (USD Million) Forecast by Biomarker Type, 2021 to 2036
- Table 10: North America Market Value (USD Million) Forecast by Cancer Type, 2021 to 2036
- Table 11: North America Market Value (USD Million) Forecast by Technology, 2021 to 2036
- Table 12: North America Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 13: Latin America Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 14: Latin America Market Value (USD Million) Forecast by Product, 2021 to 2036
- Table 15: Latin America Market Value (USD Million) Forecast by Biomarker Type, 2021 to 2036
- Table 16: Latin America Market Value (USD Million) Forecast by Cancer Type, 2021 to 2036
- Table 17: Latin America Market Value (USD Million) Forecast by Technology, 2021 to 2036
- Table 18: Latin America Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 19: Western Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 20: Western Europe Market Value (USD Million) Forecast by Product, 2021 to 2036
- Table 21: Western Europe Market Value (USD Million) Forecast by Biomarker Type, 2021 to 2036
- Table 22: Western Europe Market Value (USD Million) Forecast by Cancer Type, 2021 to 2036
- Table 23: Western Europe Market Value (USD Million) Forecast by Technology, 2021 to 2036
- Table 24: Western Europe Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 25: Eastern Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 26: Eastern Europe Market Value (USD Million) Forecast by Product, 2021 to 2036
- Table 27: Eastern Europe Market Value (USD Million) Forecast by Biomarker Type, 2021 to 2036
- Table 28: Eastern Europe Market Value (USD Million) Forecast by Cancer Type, 2021 to 2036
- Table 29: Eastern Europe Market Value (USD Million) Forecast by Technology, 2021 to 2036
- Table 30: Eastern Europe Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 31: East Asia Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 32: East Asia Market Value (USD Million) Forecast by Product, 2021 to 2036
- Table 33: East Asia Market Value (USD Million) Forecast by Biomarker Type, 2021 to 2036
- Table 34: East Asia Market Value (USD Million) Forecast by Cancer Type, 2021 to 2036
- Table 35: East Asia Market Value (USD Million) Forecast by Technology, 2021 to 2036
- Table 36: East Asia Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 37: South Asia and Pacific Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 38: South Asia and Pacific Market Value (USD Million) Forecast by Product, 2021 to 2036
- Table 39: South Asia and Pacific Market Value (USD Million) Forecast by Biomarker Type, 2021 to 2036
- Table 40: South Asia and Pacific Market Value (USD Million) Forecast by Cancer Type, 2021 to 2036
- Table 41: South Asia and Pacific Market Value (USD Million) Forecast by Technology, 2021 to 2036
- Table 42: South Asia and Pacific Market Value (USD Million) Forecast by End User, 2021 to 2036
- Table 43: Middle East & Africa Market Value (USD Million) Forecast by Country, 2021 to 2036
- Table 44: Middle East & Africa Market Value (USD Million) Forecast by Product, 2021 to 2036
- Table 45: Middle East & Africa Market Value (USD Million) Forecast by Biomarker Type, 2021 to 2036
- Table 46: Middle East & Africa Market Value (USD Million) Forecast by Cancer Type, 2021 to 2036
- Table 47: Middle East & Africa Market Value (USD Million) Forecast by Technology, 2021 to 2036
- Table 48: Middle East & Africa Market Value (USD Million) Forecast by End User, 2021 to 2036
List Of Figures
- Figure 1: Global Market Pricing Analysis
- Figure 2: Global Market Value (USD Million) Forecast 2021 to 2036
- Figure 3: Global Market Value Share and BPS Analysis by Product, 2026 and 2036
- Figure 4: Global Market Y-o-Y Growth Comparison by Product, 2026 to 2036
- Figure 5: Global Market Attractiveness Analysis by Product
- Figure 6: Global Market Value Share and BPS Analysis by Biomarker Type, 2026 and 2036
- Figure 7: Global Market Y-o-Y Growth Comparison by Biomarker Type, 2026 to 2036
- Figure 8: Global Market Attractiveness Analysis by Biomarker Type
- Figure 9: Global Market Value Share and BPS Analysis by Cancer Type, 2026 and 2036
- Figure 10: Global Market Y-o-Y Growth Comparison by Cancer Type, 2026 to 2036
- Figure 11: Global Market Attractiveness Analysis by Cancer Type
- Figure 12: Global Market Value Share and BPS Analysis by Technology, 2026 and 2036
- Figure 13: Global Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
- Figure 14: Global Market Attractiveness Analysis by Technology
- Figure 15: Global Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 16: Global Market Y-o-Y Growth Comparison by End User, 2026 to 2036
- Figure 17: Global Market Attractiveness Analysis by End User
- Figure 18: Global Market Value (USD Million) Share and BPS Analysis by Region, 2026 and 2036
- Figure 19: Global Market Y-o-Y Growth Comparison by Region, 2026 to 2036
- Figure 20: Global Market Attractiveness Analysis by Region
- Figure 21: North America Market Incremental Dollar Opportunity, 2026 to 2036
- Figure 22: Latin America Market Incremental Dollar Opportunity, 2026 to 2036
- Figure 23: Western Europe Market Incremental Dollar Opportunity, 2026 to 2036
- Figure 24: Eastern Europe Market Incremental Dollar Opportunity, 2026 to 2036
- Figure 25: East Asia Market Incremental Dollar Opportunity, 2026 to 2036
- Figure 26: South Asia and Pacific Market Incremental Dollar Opportunity, 2026 to 2036
- Figure 27: Middle East & Africa Market Incremental Dollar Opportunity, 2026 to 2036
- Figure 28: North America Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 29: North America Market Value Share and BPS Analysis by Product, 2026 and 2036
- Figure 30: North America Market Y-o-Y Growth Comparison by Product, 2026 to 2036
- Figure 31: North America Market Attractiveness Analysis by Product
- Figure 32: North America Market Value Share and BPS Analysis by Biomarker Type, 2026 and 2036
- Figure 33: North America Market Y-o-Y Growth Comparison by Biomarker Type, 2026 to 2036
- Figure 34: North America Market Attractiveness Analysis by Biomarker Type
- Figure 35: North America Market Value Share and BPS Analysis by Cancer Type, 2026 and 2036
- Figure 36: North America Market Y-o-Y Growth Comparison by Cancer Type, 2026 to 2036
- Figure 37: North America Market Attractiveness Analysis by Cancer Type
- Figure 38: North America Market Value Share and BPS Analysis by Technology, 2026 and 2036
- Figure 39: North America Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
- Figure 40: North America Market Attractiveness Analysis by Technology
- Figure 41: North America Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 42: North America Market Y-o-Y Growth Comparison by End User, 2026 to 2036
- Figure 43: North America Market Attractiveness Analysis by End User
- Figure 44: Latin America Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 45: Latin America Market Value Share and BPS Analysis by Product, 2026 and 2036
- Figure 46: Latin America Market Y-o-Y Growth Comparison by Product, 2026 to 2036
- Figure 47: Latin America Market Attractiveness Analysis by Product
- Figure 48: Latin America Market Value Share and BPS Analysis by Biomarker Type, 2026 and 2036
- Figure 49: Latin America Market Y-o-Y Growth Comparison by Biomarker Type, 2026 to 2036
- Figure 50: Latin America Market Attractiveness Analysis by Biomarker Type
- Figure 51: Latin America Market Value Share and BPS Analysis by Cancer Type, 2026 and 2036
- Figure 52: Latin America Market Y-o-Y Growth Comparison by Cancer Type, 2026 to 2036
- Figure 53: Latin America Market Attractiveness Analysis by Cancer Type
- Figure 54: Latin America Market Value Share and BPS Analysis by Technology, 2026 and 2036
- Figure 55: Latin America Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
- Figure 56: Latin America Market Attractiveness Analysis by Technology
- Figure 57: Latin America Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 58: Latin America Market Y-o-Y Growth Comparison by End User, 2026 to 2036
- Figure 59: Latin America Market Attractiveness Analysis by End User
- Figure 60: Western Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 61: Western Europe Market Value Share and BPS Analysis by Product, 2026 and 2036
- Figure 62: Western Europe Market Y-o-Y Growth Comparison by Product, 2026 to 2036
- Figure 63: Western Europe Market Attractiveness Analysis by Product
- Figure 64: Western Europe Market Value Share and BPS Analysis by Biomarker Type, 2026 and 2036
- Figure 65: Western Europe Market Y-o-Y Growth Comparison by Biomarker Type, 2026 to 2036
- Figure 66: Western Europe Market Attractiveness Analysis by Biomarker Type
- Figure 67: Western Europe Market Value Share and BPS Analysis by Cancer Type, 2026 and 2036
- Figure 68: Western Europe Market Y-o-Y Growth Comparison by Cancer Type, 2026 to 2036
- Figure 69: Western Europe Market Attractiveness Analysis by Cancer Type
- Figure 70: Western Europe Market Value Share and BPS Analysis by Technology, 2026 and 2036
- Figure 71: Western Europe Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
- Figure 72: Western Europe Market Attractiveness Analysis by Technology
- Figure 73: Western Europe Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 74: Western Europe Market Y-o-Y Growth Comparison by End User, 2026 to 2036
- Figure 75: Western Europe Market Attractiveness Analysis by End User
- Figure 76: Eastern Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 77: Eastern Europe Market Value Share and BPS Analysis by Product, 2026 and 2036
- Figure 78: Eastern Europe Market Y-o-Y Growth Comparison by Product, 2026 to 2036
- Figure 79: Eastern Europe Market Attractiveness Analysis by Product
- Figure 80: Eastern Europe Market Value Share and BPS Analysis by Biomarker Type, 2026 and 2036
- Figure 81: Eastern Europe Market Y-o-Y Growth Comparison by Biomarker Type, 2026 to 2036
- Figure 82: Eastern Europe Market Attractiveness Analysis by Biomarker Type
- Figure 83: Eastern Europe Market Value Share and BPS Analysis by Cancer Type, 2026 and 2036
- Figure 84: Eastern Europe Market Y-o-Y Growth Comparison by Cancer Type, 2026 to 2036
- Figure 85: Eastern Europe Market Attractiveness Analysis by Cancer Type
- Figure 86: Eastern Europe Market Value Share and BPS Analysis by Technology, 2026 and 2036
- Figure 87: Eastern Europe Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
- Figure 88: Eastern Europe Market Attractiveness Analysis by Technology
- Figure 89: Eastern Europe Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 90: Eastern Europe Market Y-o-Y Growth Comparison by End User, 2026 to 2036
- Figure 91: Eastern Europe Market Attractiveness Analysis by End User
- Figure 92: East Asia Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 93: East Asia Market Value Share and BPS Analysis by Product, 2026 and 2036
- Figure 94: East Asia Market Y-o-Y Growth Comparison by Product, 2026 to 2036
- Figure 95: East Asia Market Attractiveness Analysis by Product
- Figure 96: East Asia Market Value Share and BPS Analysis by Biomarker Type, 2026 and 2036
- Figure 97: East Asia Market Y-o-Y Growth Comparison by Biomarker Type, 2026 to 2036
- Figure 98: East Asia Market Attractiveness Analysis by Biomarker Type
- Figure 99: East Asia Market Value Share and BPS Analysis by Cancer Type, 2026 and 2036
- Figure 100: East Asia Market Y-o-Y Growth Comparison by Cancer Type, 2026 to 2036
- Figure 101: East Asia Market Attractiveness Analysis by Cancer Type
- Figure 102: East Asia Market Value Share and BPS Analysis by Technology, 2026 and 2036
- Figure 103: East Asia Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
- Figure 104: East Asia Market Attractiveness Analysis by Technology
- Figure 105: East Asia Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 106: East Asia Market Y-o-Y Growth Comparison by End User, 2026 to 2036
- Figure 107: East Asia Market Attractiveness Analysis by End User
- Figure 108: South Asia and Pacific Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 109: South Asia and Pacific Market Value Share and BPS Analysis by Product, 2026 and 2036
- Figure 110: South Asia and Pacific Market Y-o-Y Growth Comparison by Product, 2026 to 2036
- Figure 111: South Asia and Pacific Market Attractiveness Analysis by Product
- Figure 112: South Asia and Pacific Market Value Share and BPS Analysis by Biomarker Type, 2026 and 2036
- Figure 113: South Asia and Pacific Market Y-o-Y Growth Comparison by Biomarker Type, 2026 to 2036
- Figure 114: South Asia and Pacific Market Attractiveness Analysis by Biomarker Type
- Figure 115: South Asia and Pacific Market Value Share and BPS Analysis by Cancer Type, 2026 and 2036
- Figure 116: South Asia and Pacific Market Y-o-Y Growth Comparison by Cancer Type, 2026 to 2036
- Figure 117: South Asia and Pacific Market Attractiveness Analysis by Cancer Type
- Figure 118: South Asia and Pacific Market Value Share and BPS Analysis by Technology, 2026 and 2036
- Figure 119: South Asia and Pacific Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
- Figure 120: South Asia and Pacific Market Attractiveness Analysis by Technology
- Figure 121: South Asia and Pacific Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 122: South Asia and Pacific Market Y-o-Y Growth Comparison by End User, 2026 to 2036
- Figure 123: South Asia and Pacific Market Attractiveness Analysis by End User
- Figure 124: Middle East & Africa Market Value Share and BPS Analysis by Country, 2026 and 2036
- Figure 125: Middle East & Africa Market Value Share and BPS Analysis by Product, 2026 and 2036
- Figure 126: Middle East & Africa Market Y-o-Y Growth Comparison by Product, 2026 to 2036
- Figure 127: Middle East & Africa Market Attractiveness Analysis by Product
- Figure 128: Middle East & Africa Market Value Share and BPS Analysis by Biomarker Type, 2026 and 2036
- Figure 129: Middle East & Africa Market Y-o-Y Growth Comparison by Biomarker Type, 2026 to 2036
- Figure 130: Middle East & Africa Market Attractiveness Analysis by Biomarker Type
- Figure 131: Middle East & Africa Market Value Share and BPS Analysis by Cancer Type, 2026 and 2036
- Figure 132: Middle East & Africa Market Y-o-Y Growth Comparison by Cancer Type, 2026 to 2036
- Figure 133: Middle East & Africa Market Attractiveness Analysis by Cancer Type
- Figure 134: Middle East & Africa Market Value Share and BPS Analysis by Technology, 2026 and 2036
- Figure 135: Middle East & Africa Market Y-o-Y Growth Comparison by Technology, 2026 to 2036
- Figure 136: Middle East & Africa Market Attractiveness Analysis by Technology
- Figure 137: Middle East & Africa Market Value Share and BPS Analysis by End User, 2026 and 2036
- Figure 138: Middle East & Africa Market Y-o-Y Growth Comparison by End User, 2026 to 2036
- Figure 139: Middle East & Africa Market Attractiveness Analysis by End User
- Figure 140: Global Market - Tier Structure Analysis
- Figure 141: Global Market - Company Share Analysis
Related Reports
Oncology Companion Diagnostics Market